Last reviewed · How we verify
Cetrorelix 78+78
Cetrorelix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and follicle-stimulating hormone to inhibit ovarian steroid production.
Cetrorelix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and follicle-stimulating hormone to inhibit ovarian steroid production. Used for Hormone receptor-positive breast cancer (in combination with endocrine therapy), Ovarian cancer (hormone-sensitive).
At a glance
| Generic name | Cetrorelix 78+78 |
|---|---|
| Sponsor | AEterna Zentaris |
| Drug class | GnRH antagonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology; Reproductive/Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Cetrorelix competitively blocks GnRH receptors in the pituitary gland, rapidly suppressing the release of LH and FSH without an initial flare effect. This leads to decreased estrogen and progesterone production, making it useful for hormone-dependent conditions. The 78+78 designation likely refers to a dual-dose formulation or dosing regimen in development.
Approved indications
- Hormone receptor-positive breast cancer (in combination with endocrine therapy)
- Ovarian cancer (hormone-sensitive)
Common side effects
- Hot flashes
- Headache
- Injection site reactions
- Fatigue
- Nausea
Key clinical trials
- Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) (PHASE3)
- Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) (PHASE3)
- Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |